The Phase II study for DSC127, which will be focused on diabetic foot ulcers, is scheduled to begin enrollment in the third quarter of 2008. Derma Sciences obtained the rights to DSC127 via license with the University of Southern California, and has also signed a clinical services agreement with US Biotest. The scope of the agreement covers pre-study services, study management, clinical operations, data management and medical writing.
Ed Quilty, CEO of Derma Sciences, said: “The development of DSC127 is an important milestone for Derma Sciences because it represents an opportunity for us to enter two of the largest and fastest-growing wound care markets in the world today.”